CureVac
Employee Participants0
Total Rating0
Revenue$0
Developer of mRNA-molecules for therapeutic and prophylactic vaccines. The company has developed RNAdjuvant that enhances the immune response to a large number of different vaccines, including protein and peptide-based vaccines, without toxic effects. Read More
Headquarters Paul-Ehrlich-Str. 15, 72076, DEU
Website www.curevac.com
60/100